Stephen J. Barigye

Stephen J. Barigye

Auto-generated profile, based on publicly available information

Stephen J. Barigye

Departamento de Química Física Aplicada, Facultad de Ciencias, Universidad Autónoma de Madrid (UAM), 28049 Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2017 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
JVJosé R. Valdés-Martiní
José R. Valdés-Martiní
Yovani Marrero-PonceYovani Marrero-Ponce
Yovani Marrero-Ponce
CGCesar Raul Garcia-Jacas
Cesar Raul Garcia-Jacas
KMKarina Martinez-Mayorga
Karina Martinez-Mayorga
SBStephen J. Barigye
Stephen J. Barigye
CMCarlos A. Morell
Carlos A. Morell
In previous reports, Marrero-Ponce et al. proposed algebraic formalisms for characterizing topological (2D) and chiral (2.5D) molecular features through atom- and bond-based ToMoCoMD-CARDD (acronym for Topological Molecular Computational Design-Computer Aided Rational Drug Design) molecular descriptors. These MDs codify molecular information based on the bilinear, quadratic and linear algebraic forms and the graph-theoretical electronic-density and edge-adjacency matrices in order to consider atom- and bond-based relations, respectively. These MDs have been successfully applied in the screening of chemical compounds of different therapeutic applications ranging from antimalarials, antibacterials, tyrosinase inhibitors and so on. To compute these MDs, a computational program with the same name was initially developed. However, this in house software barely offered the functionalities required in contemporary molecular modeling tasks, in addition to the inherent limitations that made its usability impractical. Therefore, the present manuscript introduces the QuBiLS-MAS (acronym for Quadratic, Bilinear and N-Linear mapS based on graph-theoretic electronic-density Matrices and Atomic weightingS) software designed to compute topological (0–2.5D) molecular descriptors based on bilinear, quadratic and linear algebraic forms for atom- and bond-based relations. The QuBiLS-MAS module was designed as standalone software, in which extensions and generalizations of the former ToMoCoMD-CARDD 2D-algebraic indices are implemented, considering the following aspects: (a) two new matrix normalization approaches based on double-stochastic and mutual probability formalisms; (b) topological constraints (cut-offs) to take into account particular inter-atomic relations; (c) six additional atomic properties to be used as weighting schemes in the calculation of the molecular vectors; (d) four new local-fragments to consider molecular regions of interest; (e) number of lone-pair electrons in chemical structure defined by diagonal coefficients in matrix representations; and (f) several aggregation operators (invariants) applied over atom/bond-level descriptors in order to compute global indices. This software permits the parallel computation of the indices, contains a batch processing module and data curation functionalities. This program was developed in Java v1.7 using the Chemistry Development Kit library (version 1.4.19). The QuBiLS-MAS software consists of two components: a desktop interface (GUI) and an API library allowing for the easy integration of the latter in chemoinformatics applications. The relevance of the novel extensions and generalizations implemented in this software is demonstrated through three studies. Firstly, a comparative Shannon’s entropy based variability study for the proposed QuBiLS-MAS and the DRAGON indices demonstrates superior performance for the former. A principal component analysis reveals that the QuBiLS-MAS approach captures chemical information orthogonal to that codified by the DRAGON descriptors. Lastly, a QSAR study for the binding affinity to the corticosteroid-binding globulin using Cramer’s steroid dataset is carried out. From these analyses, it is revealed that the QuBiLS-MAS approach for atom-pair relations yields similar-to-superior performance with regard to other QSAR methodologies reported in the literature. Therefore, the QuBiLS-MAS approach constitutes a useful tool for the diversity analysis of chemical compound datasets and high-throughput screening of structure–activity data.

29 March 2015 in Bioinformatics
Verified
Journal Article
Open access
PDF file
LALongendri Aguilera-Mendoza
Longendri Aguilera-Mendoza
Yovani Marrero-PonceYovani Marrero-Ponce
Yovani Marrero-Ponce
RTRoberto Tellez-Ibarra
Roberto Tellez-Ibarra
MLMonica T. Llorente-Quesada
Monica T. Llorente-Quesada
JSJesús Salgado
Jesús Salgado
JLJun Liu
Jun Liu
Motivation: The large variety of antimicrobial peptide (AMP) databases developed to date are characterized by a substantial overlap of data and similarity of sequences. Our goals are to analyze the levels of redundancy for all available AMP databases and use this information to build a new non-redundant sequence database. For this purpose, a new software tool is introduced. Results: A comparative study of 25 AMP databases reveals the overlap and diversity among them and the internal diversity within each database. The overlap analysis shows that only one database (Peptaibol) contains exclusive data, not present in any other, whereas all sequences in the LAMP_Patent database are included in CAMP_Patent. However, the majority of databases have their own set of unique sequences, as well as some overlap with other databases. The complete set of non-duplicate sequences comprises 16 990 cases, which is almost half of the total number of reported peptides. On the other hand, the diversity analysis identifies the most and least diverse databases and proves that all databases exhibit some level of redundancy. Finally, we present a new parallel-free software, named Dover Analyzer, developed to compute the overlap and diversity between any number of databases and compile a set of non-redundant sequences. These results are useful for selecting or building a suitable representative set of AMPs, according to specific needs. Availability and implementation: The regularly updated non-redundant sequence databases and the Dover Analyzer software to perform custom analysis are available at http://mobiosd-hub.com/doveranalyzer/. Contact:ymarrero77@yahoo.es Supplementary information: Supplementary data are available at Bioinformatics online.

24 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
CPCesar Paz-y-Mino
Cesar Paz-y-Mino
SGSantiago Guerrero
Santiago Guerrero
Alejandro Cabrera-AndradeAlejandro Cabrera-Andrade
Alejandro Cabrera-Andrade
SBStephen J. Barigye
Stephen J. Barigye
ETEduardo Tejera
Eduardo Tejera
Breast cancer (BC) is the leading cause of cancer-related death among women and the most commonly diagnosed cancer worldwide. Although in recent years large-scale efforts have focused on identifying new therapeutic targets, a better understanding of BC molecular processes is required. Here we focused on elucidating the molecular hallmarks of BC heterogeneity and the oncogenic mutations involved in precision medicine that remains poorly defined. To fill this gap, we established an OncoOmics strategy that consists of analyzing genomic alterations, signaling pathways, protein-protein interactome network, protein expression, dependency maps in cell lines and patient-derived xenografts in 230 previously prioritized genes to reveal essential genes in breast cancer. As results, the OncoOmics BC essential genes were rationally filtered to 140. mRNA up-regulation was the most prevalent genomic alteration. The most altered signaling pathways were associated with basal-like and Her2-enriched molecular subtypes. RAC1, AKT1, CCND1, PIK3CA, ERBB2, CDH1, MAPK14, TP53, MAPK1, SRC, RAC3, BCL2, CTNNB1, EGFR, CDK2, GRB2, MED1 and GATA3 were essential genes in at least three OncoOmics approaches. Drugs with the highest amount of clinical trials in phases 3 and 4 were paclitaxel, docetaxel, trastuzumab, tamoxifen and doxorubicin. Lastly, we collected ~3,500 somatic and germline oncogenic variants associated with 50 essential genes, which in turn had therapeutic connectivity with 73 drugs. In conclusion, the OncoOmics strategy reveals essential genes capable of accelerating the development of targeted therapies for precision oncology.

26 January 2015 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
RURicardo W. Pino Urias
Ricardo W. Pino Urias
SBStephen J. Barigye
Stephen J. Barigye
Yovani Marrero-PonceYovani Marrero-Ponce
Yovani Marrero-Ponce
CGCesar Raul Garcia-Jacas
Cesar Raul Garcia-Jacas
JVJosé R. Valdes-Martiní
José R. Valdes-Martiní
FPFacundo Perez-Gimenez
Facundo Perez-Gimenez

7 May 2015 in Molecular Informatics
Verified
Journal Article
Closed access
PDF file
YBYoan Brito‐Sánchez
Yoan Brito‐Sánchez
Yovani Marrero-PonceYovani Marrero-Ponce
Yovani Marrero-Ponce
SBStephen J. Barigye
Stephen J. Barigye
IYIván Yaber‐Goenaga
Iván Yaber‐Goenaga
CPCarlos Morell Pérez
Carlos Morell Pérez
ACArtem Cherkasov
Artem Cherkasov

2 June 2014 in Journal of Computational Chemistry
Verified
Journal Article
Closed access
PDF file
CGCesar Raul Garcia-Jacas
Cesar Raul Garcia-Jacas
Yovani Marrero-PonceYovani Marrero-Ponce
Yovani Marrero-Ponce
LALiesner Acevedo‐Martínez
Liesner Acevedo‐Martínez
SBStephen J. Barigye
Stephen J. Barigye
JVJosé R. Valdés‐Martiní
José R. Valdés‐Martiní
Ernesto Contreras-TorresErnesto Contreras-Torres
Ernesto Contreras-Torres